We are live on ! Find out more
TCM

Tang Capital Management Portfolio holdings

AUM $1.97B
1-Year Est. Return 125.1%
This Fund
S&P 500
This Quarter Est. Return
-0.55%
1 Year Est. Return
+125.1%
3 Year Est. Return
+474.48%
5 Year Est. Return
+595.08%
10 Year Est. Return
+2,831.44%
AUM
$1.51B
AUM Growth
+$111M
Cap. Flow
+$272M
Cap. Flow %
17.99%
Top 10 Hldgs %
37.54%
Holding
194
New
40
Increased
63
Reduced
17
Closed
11

Top Buys

Rank Stock Value
1
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$40.7M
2
RLAY icon
Relay Therapeutics
RLAY
+$24.5M
3
BIOA
BioAge Labs
BIOA
+$22.7M
4
LEGN icon
Legend Biotech
LEGN
+$18.6M
5
REPL icon
Replimune Group
REPL
+$18.2M

Top Sells

Rank Stock Value
1
ITOS
iTeos Therapeutics
ITOS
+$18.8M
2
RVNC
Revance Therapeutics, Inc.
RVNC
+$13M
3
IMNM icon
Immunome
IMNM
+$10.5M
4
ANIP icon
ANI Pharmaceuticals
ANIP
+$7.61M
5
CNTA
Centessa Pharmaceuticals
CNTA
+$6.4M

Sector Composition

Rank Sector Weight
1 Healthcare 94.65%
2 Technology 1.65%
3 Communication Services 1.35%
4 Consumer Discretionary 0.56%
5 Financials 0.53%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MCD icon
151
McDonald's
MCD
$195B
$975K 0.06%
+3,365
New +$1M
WHR icon
152
Whirlpool
WHR
$2.82B
$974K 0.06%
+8,510
New +$939K
KRON
153
DELISTED
Kronos Bio
KRON
$953K 0.06%
+1,003,382
New +$947K
SEE
154
DELISTED
Sealed Air
SEE
$952K 0.06%
+28,132
New +$1M
FDX icon
155
FedEx
FDX
$75.4B
$942K 0.06%
+3,349
New +$935K
SHW icon
156
Sherwin-Williams
SHW
$89.8B
$940K 0.06%
2,765
+2,153
+352% +$804K
IPSC icon
157
Century Therapeutics
IPSC
$361M
$909K 0.06%
900,000
– –
ATXS
158
DELISTED
Astria Therapeutics
ATXS
$894K 0.06%
100,000
– –
GEV icon
159
GE Vernova
GEV
$264B
$891K 0.06%
+2,710
New +$847K
MRNS
160
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$879K 0.06%
1,641,945
-3,058,055
-65% -$2.13M
KURA icon
161
Kura Oncology
KURA
$850M
$871K 0.06%
100,000
– –
CVX icon
162
Chevron
CVX
$366B
$866K 0.06%
+5,978
New +$915K
PASG icon
163
Passage Bio
PASG
$14.1M
$851K 0.06%
75,000
– –
F icon
164
Ford
F
$55.7B
$849K 0.06%
85,749
+72,976
+571% +$778K
BCAB icon
165
BioAtla
BCAB
$5.74M
$812K 0.05%
27,482
+10,000
+57% +$839K
ENTA icon
166
Enanta Pharmaceuticals
ENTA
$400M
$728K 0.05%
126,655
– –
LAB icon
167
Standard BioTools
LAB
$314M
$714K 0.05%
407,755
– –
MGNX icon
168
MacroGenics
MGNX
$257M
$711K 0.05%
218,856
– –
LXRX icon
169
Lexicon Pharmaceuticals
LXRX
$1.1B
$628K 0.04%
850,268
+750,268
+750% +$904K
PBYI icon
170
Puma Biotechnology
PBYI
$454M
$610K 0.04%
200,000
– –
NXTC icon
171
NextCure
NXTC
$26.7M
$540K 0.04%
58,333
+3,967
+7% +$58.4K
EDIT icon
172
Editas Medicine
EDIT
$442M
$508K 0.03%
+400,000
New +$1.02M
ALLK
173
DELISTED
Allakos
ALLK
$458K 0.03%
378,552
+333,290
+736% +$350K
AMLX icon
174
Amylyx Pharmaceuticals
AMLX
$2.54B
$378K 0.03%
100,000
– –
TCRX icon
175
TScan Therapeutics
TCRX
$52M
$358K 0.02%
+117,847
New +$534K
4 5 6
7
8

Similar funds

HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BC
Blackhill Capital Morristown, New Jersey $1.94B AUM 18.09% 1-Year Est. Return
FFH
Fairfax Financial Holdings Toronto, Ontario, Canada $1.94B AUM 27.76% 1-Year Est. Return

Tang Capital Management's Q4 2024 Portfolio in Review

As of Q4 2024, Tang Capital Management held 194 positions worth $1.51B, up 8% from $1.4B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Tang Capital Management deployed $272M of net new capital in Q4 2024, opening 40 new positions and adding to 63 existing holdings. Its largest new stake was BioAge Labs: 1,318,361 shares worth $7.63M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 96% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was iTeos Therapeutics, an estimated $18.8M trimmed.

  • Tang Capital Management's largest Q4 2024 buy was BioAge Labs: 1,318,361 shares worth $7.63M.
  • Tang Capital Management added most to Lakefront Biotherapeutics American Depositary Shares in Q4 2024, an estimated $40.7M increase.
  • Tang Capital Management's biggest Q4 2024 reduction was iTeos Therapeutics, cutting an estimated $18.8M.
  • Tang Capital Management fully exited Revance Therapeutics, Inc. in Q4 2024, selling an estimated $13M.
  • Tang Capital Management's ten largest holdings make up 38% of its $1.51B portfolio in Q4 2024.
  • Tang Capital Management opened 40 new positions and closed 11 in Q4 2024.
  • Tang Capital Management's portfolio value rose 8% quarter-over-quarter to $1.51B.

Based on Tang Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.